Trial Profile
A Randomized, Open-Label, Parallel-Arm, Noninferiority Comparison of the Effects of Two Doses of LY2189265 and Insulin Glargine on Glycemic Control in Patients with Type 2 Diabetes on Stable Doses of Metformin and Glimepiride (AWARD-2: Assessment of Weekly AdministRation of LY2189265 in Diabetes-2)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Dulaglutide (Primary) ; Glimepiride; Insulin glargine; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms AWARD-2
- Sponsors Eli Lilly and Company
- 01 Apr 2022 Results of post-hoc pooled analysis of six studies (AWARD-1, -2, -3, -6, -8 and -9) assessing association between treatment with dulaglutide and glycaemic variability in adult patients with type 2 diabetes mellitus, published in the Diabetes, Obesity and Metabolism.
- 16 Dec 2021 This trial has been completed in France, according to European Clinical Trials Database record.
- 16 Jun 2020 Results from AWARD- 2 and AWARD-9 presented at the 80th Annual Scientific Sessions of the American Diabetes Association